Famotidine: A supplemental drug for the treatment of schizophrenia

European Psychiatry

Volumn 12, Issue 5, 1997, Pages 263-264

  Dannon, P N ^a   Lepkifker, E ^a   Iancu, I ^a   Ziv, R ^a   Horesh, N ^a   Kotler, M ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Famotidine; H2 receptor antagonists; Neuroleptics; Schizophrenia

Indexed keywords

FAMOTIDINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030835767     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)83302-0     Document Type: Article

References (9)

1. Carpenter W, Buchanan R. Schizophrenia (A Review). N Engl J Med 1994;330:681-8
2. Chermos AN. Pharmacodynamics of famotidine in humans. Am J Med 1986;84(suppl 4B):3-7
3. Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993;16: 518-24
4. Hough LB. Cellular localization and possible functions for brain histamine: recent progress. Prog Neurobiol 1988;30: 469-505
5. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1989;335:1351-2
6. Rifkin A. Pharmacological strategies in the treatment of schizophrenia. Psych Clin of North America 1993;16:351-62
7. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996;19:341-8
8. White JM, Rumbold GR. Behavioral effects of histamine and its antagonists: a review. Psychopharmacology 1988;95:1-4
9. Yoshimoto K, Saima S, Echizen H, Nakamura Y et al. Famotidine-associated CNS reactions and plasma and CS drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther 1994;55:693-700